Vernal keratoconjunctivitis market size is expected to grow in the forecasted period 2020-2030

Rising prevalence, launch of new therpaies, incremental healthcare spending, heightened R&D, improved reimbursement policies and a better understanding of the disease are the major Vernal keratoconjunctivitis market drivers.

LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- DelveInsight has launched a new report 'Vernal keratoconjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030' in its repository.

Report Findings

• The Vernal keratoconjunctivitis (VKC) market size in the geographies including 7MM, Saudi Arabia and Egypt, Russia and China is expected to increase during the study period.
• As per the historical analysis, China accounted for the highest Vernal keratoconjunctivitis market size among all the geographies for the study period 2017-30, followed by Japan and Russia.
• Total Vernal keratoconjunctivitis prevalent population in the total market (7MM, China, Egypt, Saudi Arabia and Russia) in 2019 was 4,801,929
• Of the emerging therapies, the most anticipated product to get launched is the AK002 (Allakos).
• Key pharma and biotech players profoundly working to give momentum to the Vernal keratoconjunctivitis market are Allakos, iCo Therapeutics, Akari Therapeutics, Santen and many others.

Request for Free Sample Pages of the Report: https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market 

A relatively rare form of ocular allergy, Vernal keratoconjunctivitis (VKC) can result into severe visual complications. VKC is an IgE- and T-cell meditated disease, causing a chronic inflammation with non-specific, barely understood hypersensitivity responses. The ocular allergy is characterized by conjunctival hyperemia, itching, photophobia, and tearing, with symptoms usually more severe during spring and summer.

Vernal keratoconjunctivitis prevalence is relatively higher in dry and hot climates (Mediterranean areas, Central and West Africa, and South America), however, it has a wide geographical distribution.

• As per DelveInsight estimates, total Vernal keratoconjunctivitis prevalent population in the total market (7MM, China, Egypt, Saudi Arabia and Russia) is increasing in the study period. Among all the geographies, China was observed to account for the maximum VKC prevalence
• Furthermore, a higher percentage of diagnosed Vernal keratoconjunctivitis prevalence was observed in males, in comparison to females, during the study period 2017-30. Majority of the patient pool was estimated to be of the age-group 0–20 years old with an age of onset between 10–12 years old; however, there are reports of patients as young as 5-months-o
• Based on the subtypes, Palpebral Vernal keratoconjunctivitis accounted for the majority of the total prevalent cases approximately 48%, whereas Bulbar VKC accounted for approximately 44% of the total VKC cases with rest 8% were designated mixed.

The Vernal keratoconjunctivitis market report proffers in depth epidemiological segmentation analysis for the study period 2017-30, the epidemiology for this disease is segmented as following in the report:

• Total Prevalent Population
• Diagnosed Prevalent Population
• Gender-specific Diagnosed Prevalent Population
• Type-specific Diagnosed Prevalent Population
• Severity-specific Diagnosed Prevalent Population and
• Age-specific Diagnosed Prevalent Population

Vernal keratoconjunctivitis Market

Treatment of Vernal keratoconjunctivitis requires multiple approaches that include conservative measures and pharmacologic treatment. The present Vernal keratoconjunctivitis treatment market comprises mast cell stabilizers, vasoconstrictors, antihistamines, 'dual-acting' agents (with antihistaminic and mast cell stabilizing properties), nonsteroidal anti-inflammatory drugs (NSAIDs), topical corticosteroids, cyclosporine, tacrolimus, and immunosuppressive drugs.

The treatment is only supportive in nature and is not that effective. However, with the advancement of technology and a better understanding of the pathophysiology of the disease several novel emerging therapies are in the horizon to advance Vernal keratoconjunctivitis market.

However, there exists no defined or standard care for the VKC patients. VKC treatment algorithm requires to be tailored as per patients 'requirements with proper understanding of the duration of the treatment regimen and a careful monitoring for the corneal complications.

Vernal keratoconjunctivitis Marketed Drugs

• Verkazia/Verkacia: Santen
• Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon
• Talymus/Tacrolimus: Senju Pharmaceutical

As per DelveInsight, global Vernal keratoconjunctivitis market is expected to change in the study period 2017–2030. With the launch of therapies in the VKC pipeline such as Verkazia (Santen), AK002 (Allakos), Bertilimumab/iCo-008 (iCo Therapeutics), and Nomacopan (Akari Therapeutics) in the US, the Vernal keratoconjunctivitis market size is expected to grow in the forecasted period 2020–30. Out of the emerging therapies, the most anticipated product to get launched and occupy the major chunk of Vernal keratoconjunctivitis market share is the AK002 (Allakos).

Furthermore, there are other companies who have their drugs in the early pre-clinical phases of development such as including Postbiotica and Sylentis, hence the launch of their therapies is expected further after in the forecasted period.

Vernal keratoconjunctivitis Pipeline Drugs

• Antolimab (AK002): Allakos
• Bertilimumab/iCo-008: iCo Therapeutics
• Nomacopan: Akari Therapeutics
• Verkazia: Santen

With only limited treatment option available in the market, there are lucrative opportunities for the pharma players in the Vernal keratoconjunctivitis market to dominate and grow. Moreover, the current pipeline appears weak, which further becomes a significant inviting factor for the companies to explore the VKC market. However, poor diagnostic modalities, easy availability of OTC medications, generics and strict reimbursement policies are expected to obstruct and slow down the Vernal keratoconjunctivitis market growth.

Identify Key Trends of Vernal keratoconjunctivitis Market: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market

Scope of the Report

• Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, MEA (Saudi Arabia, Egypt), China and Russia.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Markets Segmentation: By Geographies, By Therapies, By Line of Therapies
• Companies Covered: Allakos, iCo Therapeutics, Akari Therapeutics, Santen and others.
• Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis,
• Case Studies
• KOL's Views
• Analyst's View

Reason to purchase

• Bespoke primary and secondary research
• 24*7 post-sale customer support
• Option for customizing and personalizing research reports as per needs

Table of Contents

Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market

Related Reports

Vernal Keratoconjunctivitis - Epidemiology Forecast to 2030

DelveInsight's 'Vernal Keratoconjunctivitis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the 7MM - the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, MEA (Saudi Arabia and Egypt) and Russia.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:
Shruti Thakur
info@delveinsight.com
+91-9650213330

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg